Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Biological | 11 | 2019 | 392 | 1.730 |
Why?
|
| Breast Neoplasms | 7 | 2022 | 754 | 1.630 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 66 | 1.250 |
Why?
|
| Models, Theoretical | 5 | 2020 | 138 | 1.210 |
Why?
|
| Fracture Healing | 5 | 2012 | 43 | 0.920 |
Why?
|
| Brain Neoplasms | 6 | 2019 | 647 | 0.770 |
Why?
|
| Spheroids, Cellular | 1 | 2020 | 38 | 0.650 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2019 | 1307 | 0.600 |
Why?
|
| Radiation Injuries | 1 | 2019 | 78 | 0.570 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 4 | 2012 | 82 | 0.530 |
Why?
|
| Treatment Outcome | 6 | 2022 | 3441 | 0.490 |
Why?
|
| Cell Proliferation | 5 | 2022 | 603 | 0.490 |
Why?
|
| Surgery, Computer-Assisted | 5 | 2017 | 57 | 0.490 |
Why?
|
| Glioma | 4 | 2018 | 136 | 0.470 |
Why?
|
| Radiosurgery | 1 | 2019 | 362 | 0.470 |
Why?
|
| Bony Callus | 3 | 2012 | 3 | 0.420 |
Why?
|
| Mechanical Phenomena | 1 | 2013 | 28 | 0.400 |
Why?
|
| X-Ray Microtomography | 2 | 2012 | 41 | 0.400 |
Why?
|
| Tibial Fractures | 2 | 2009 | 33 | 0.380 |
Why?
|
| Animals | 18 | 2021 | 7570 | 0.340 |
Why?
|
| Bone Density | 1 | 2012 | 203 | 0.330 |
Why?
|
| Fractures, Bone | 1 | 2012 | 162 | 0.330 |
Why?
|
| Female | 18 | 2022 | 20271 | 0.320 |
Why?
|
| Neoplasms | 4 | 2019 | 762 | 0.300 |
Why?
|
| Recovery of Function | 1 | 2009 | 203 | 0.290 |
Why?
|
| Mesenchymal Stem Cells | 4 | 2012 | 182 | 0.290 |
Why?
|
| Medical Oncology | 3 | 2019 | 92 | 0.280 |
Why?
|
| Humans | 23 | 2022 | 32814 | 0.280 |
Why?
|
| Mice | 10 | 2020 | 2512 | 0.250 |
Why?
|
| Cell Line, Tumor | 4 | 2020 | 727 | 0.220 |
Why?
|
| Algorithms | 4 | 2018 | 511 | 0.220 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2017 | 134 | 0.220 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 599 | 0.210 |
Why?
|
| Liver | 2 | 2017 | 492 | 0.210 |
Why?
|
| Gastric Mucosa | 2 | 2020 | 13 | 0.200 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2015 | 112 | 0.200 |
Why?
|
| Retrospective Studies | 2 | 2022 | 3705 | 0.190 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2012 | 83 | 0.180 |
Why?
|
| Elastic Modulus | 2 | 2012 | 27 | 0.170 |
Why?
|
| Paneth Cells | 1 | 2021 | 4 | 0.170 |
Why?
|
| Ileum | 1 | 2021 | 16 | 0.170 |
Why?
|
| Lymphocyte Subsets | 1 | 2020 | 6 | 0.170 |
Why?
|
| Biophysical Phenomena | 1 | 2020 | 6 | 0.170 |
Why?
|
| Finite Element Analysis | 2 | 2012 | 83 | 0.160 |
Why?
|
| Intestinal Mucosa | 1 | 2021 | 73 | 0.160 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2020 | 14 | 0.160 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2021 | 28 | 0.160 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2020 | 55 | 0.160 |
Why?
|
| Hepatectomy | 2 | 2017 | 56 | 0.160 |
Why?
|
| Placenta | 1 | 2021 | 75 | 0.160 |
Why?
|
| Immunity, Innate | 1 | 2020 | 76 | 0.160 |
Why?
|
| Cell Survival | 1 | 2020 | 281 | 0.150 |
Why?
|
| Stem Cell Transplantation | 1 | 2021 | 212 | 0.150 |
Why?
|
| Apoptosis | 1 | 2021 | 362 | 0.150 |
Why?
|
| Necrosis | 1 | 2019 | 51 | 0.150 |
Why?
|
| Recurrence | 1 | 2019 | 282 | 0.140 |
Why?
|
| Biostatistics | 1 | 2017 | 8 | 0.130 |
Why?
|
| Gravitation | 1 | 2017 | 5 | 0.130 |
Why?
|
| Cranial Irradiation | 1 | 2017 | 93 | 0.130 |
Why?
|
| Diffusion | 2 | 2015 | 14 | 0.130 |
Why?
|
| Computer Simulation | 3 | 2018 | 223 | 0.130 |
Why?
|
| Rats, Wistar | 4 | 2018 | 79 | 0.130 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 145 | 0.130 |
Why?
|
| Cell Transdifferentiation | 1 | 2016 | 6 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 69 | 0.130 |
Why?
|
| Chief Cells, Gastric | 1 | 2016 | 4 | 0.130 |
Why?
|
| Doxorubicin | 1 | 2017 | 84 | 0.130 |
Why?
|
| Stomach | 1 | 2016 | 17 | 0.130 |
Why?
|
| Breast | 1 | 2017 | 64 | 0.130 |
Why?
|
| Parietal Cells, Gastric | 2 | 2016 | 9 | 0.130 |
Why?
|
| Cell Lineage | 1 | 2016 | 71 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 576 | 0.130 |
Why?
|
| Peptides | 2 | 2016 | 125 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 154 | 0.120 |
Why?
|
| Molecular Imaging | 1 | 2016 | 20 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2016 | 87 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2015 | 92 | 0.120 |
Why?
|
| Mastectomy, Segmental | 1 | 2015 | 27 | 0.120 |
Why?
|
| ROC Curve | 1 | 2015 | 168 | 0.110 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2014 | 1 | 0.110 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 22 | 0.110 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 1012 | 0.110 |
Why?
|
| Calcinosis | 1 | 2014 | 146 | 0.100 |
Why?
|
| Adult | 3 | 2017 | 9569 | 0.100 |
Why?
|
| Mice, Knockout | 4 | 2020 | 453 | 0.100 |
Why?
|
| Cell Division | 1 | 2013 | 94 | 0.100 |
Why?
|
| Metaplasia | 3 | 2020 | 19 | 0.100 |
Why?
|
| Clusterin | 1 | 2012 | 6 | 0.090 |
Why?
|
| Helicobacter Infections | 1 | 2012 | 9 | 0.090 |
Why?
|
| Artifacts | 1 | 2012 | 42 | 0.090 |
Why?
|
| Bone Regeneration | 2 | 2009 | 33 | 0.090 |
Why?
|
| Image Enhancement | 1 | 2012 | 70 | 0.090 |
Why?
|
| Intestines | 1 | 2012 | 60 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2012 | 151 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 457 | 0.090 |
Why?
|
| Prognosis | 1 | 2015 | 1545 | 0.090 |
Why?
|
| Brain | 1 | 2018 | 946 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 767 | 0.080 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 96 | 0.080 |
Why?
|
| Regenerative Medicine | 2 | 2012 | 202 | 0.080 |
Why?
|
| Inflammation | 1 | 2012 | 536 | 0.070 |
Why?
|
| Rats | 3 | 2017 | 1606 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2019 | 54 | 0.070 |
Why?
|
| Bone Diseases | 1 | 2008 | 19 | 0.070 |
Why?
|
| Cartilage Diseases | 1 | 2008 | 21 | 0.070 |
Why?
|
| Morphogenesis | 1 | 2007 | 5 | 0.070 |
Why?
|
| Joints | 1 | 2007 | 12 | 0.070 |
Why?
|
| Bone and Bones | 3 | 2014 | 94 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 60 | 0.060 |
Why?
|
| Young Adult | 1 | 2013 | 2734 | 0.060 |
Why?
|
| Wound Healing | 2 | 2021 | 188 | 0.060 |
Why?
|
| Aged | 2 | 2017 | 10544 | 0.060 |
Why?
|
| Middle Aged | 2 | 2017 | 12133 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2016 | 98 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2007 | 687 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2012 | 247 | 0.040 |
Why?
|
| SOX9 Transcription Factor | 1 | 2021 | 12 | 0.040 |
Why?
|
| Stem Cell Niche | 1 | 2021 | 27 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2021 | 119 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2021 | 84 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 102 | 0.040 |
Why?
|
| Cytokines | 1 | 2021 | 247 | 0.040 |
Why?
|
| Macromolecular Substances | 1 | 2019 | 15 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2019 | 69 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 72 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2021 | 820 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 754 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 94 | 0.040 |
Why?
|
| Oxygen | 1 | 2019 | 144 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 220 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2018 | 91 | 0.030 |
Why?
|
| Cell Death | 1 | 2017 | 71 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2017 | 61 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 981 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 225 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2017 | 84 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 126 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2017 | 44 | 0.030 |
Why?
|
| Software | 1 | 2018 | 124 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 30 | 0.030 |
Why?
|
| Contrast Media | 1 | 2017 | 139 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 195 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2017 | 59 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2016 | 44 | 0.030 |
Why?
|
| Supine Position | 1 | 2015 | 10 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2015 | 10 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 779 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2015 | 52 | 0.030 |
Why?
|
| Reoperation | 1 | 2015 | 260 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 307 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 1197 | 0.030 |
Why?
|
| Mice, Inbred CFTR | 1 | 2012 | 2 | 0.020 |
Why?
|
| Azetidines | 1 | 2012 | 10 | 0.020 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2012 | 12 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 37 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2012 | 25 | 0.020 |
Why?
|
| Piperazines | 1 | 2012 | 52 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 2285 | 0.020 |
Why?
|
| Cell Migration Assays | 1 | 2011 | 2 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2012 | 191 | 0.020 |
Why?
|
| Retroviridae | 1 | 2011 | 28 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2012 | 114 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2011 | 60 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2011 | 81 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 184 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2011 | 120 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 316 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 565 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 475 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 949 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2009 | 11 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2009 | 26 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2009 | 21 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2009 | 67 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2011 | 468 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 789 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 28 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2007 | 10 | 0.020 |
Why?
|
| Cartilage, Articular | 1 | 2008 | 75 | 0.020 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2007 | 49 | 0.020 |
Why?
|
| Extremities | 1 | 2007 | 54 | 0.020 |
Why?
|
| Male | 1 | 2017 | 19650 | 0.010 |
Why?
|